A steering committee and task force was convened to develop recommendations for the use of Janus kinase (JAK) inhibitors in the treatment of immune-mediated inflammatory diseases (IMID).
All News
The SELECT-PsA 2 trial was presented at the ACR meeting and recently published in Annals of Rheumatic Disease, shows that psoriatic arthritis (PsA) patients who have failed at least one biologic DMARD, did respond well to upadacitinib.
Dr. Jeffrey Curtis examines abstracts #1997 and #0452 presented at the ACR 2020 annual meeting.
Here are my highlights from day four, Monday, of the ACR 2020 Convergence.
Vaccine Immunogenicity with Tofacitinib
Investigations on the efficacy and safety of JAK inhibitors as a therapeutic option in the management of AS are increasing.
Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu
